このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Morphic Holding 配当金

配当金基準チェック /06

Morphic Holding配当金を支払った記録がありません。

主要情報

n/a

配当利回り

n/a

配当性向

業界平均利回り	2.8%
次回配当支払日	n/a
配当落ち日	n/a
一株当たり配当金	n/a
一株当たり利益	-US$3.22
3年後の配当利回り予想	n/a

最近の配当金アップデート

更新なし

Recent updates

Here's Why We're Not Too Worried About Morphic Holding's (NASDAQ:MORF) Cash Burn Situation

Jun 26

We're Hopeful That Morphic Holding (NASDAQ:MORF) Will Use Its Cash Wisely

Jan 20

Companies Like Morphic Holding (NASDAQ:MORF) Are In A Position To Invest In Growth

Sep 29

We're Interested To See How Morphic Holding (NASDAQ:MORF) Uses Its Cash Hoard To Grow

Jun 07

What Does The Future Hold For Morphic Holding, Inc. (NASDAQ:MORF)? These Analysts Have Been Cutting Their Estimates

Feb 15

We're Hopeful That Morphic Holding (NASDAQ:MORF) Will Use Its Cash Wisely

Jan 03

What Does The Future Hold For Morphic Holding, Inc. (NASDAQ:MORF)? These Analysts Have Been Cutting Their Estimates

Nov 08

Morphic GAAP EPS of -$0.68 beats by $0.17, revenue of $60.2M

Aug 03

Revenue Downgrade: Here's What Analysts Forecast For Morphic Holding, Inc. (NASDAQ:MORF)

May 06

Analyst Forecasts Just Became More Bearish On Morphic Holding, Inc. (NASDAQ:MORF)

Mar 01

Here's Why We're Not Too Worried About Morphic Holding's (NASDAQ:MORF) Cash Burn Situation

Feb 17

Independent Director Vikas Goyal Just Bought A Handful Of Shares In Morphic Holding, Inc. (NASDAQ:MORF)

Mar 09

Did Business Growth Power Morphic Holding's (NASDAQ:MORF) Share Price Gain of 126%?

Feb 24

How Many Morphic Holding, Inc. (NASDAQ:MORF) Shares Have Insiders Sold, In The Last Year?

Jan 20

Morphic Holding (MORF) Presents At 39th Annual Healthcare Conference - Slideshow

Jan 14

Companies Like Morphic Holding (NASDAQ:MORF) Can Afford To Invest In Growth

Dec 16

決済の安定と成長

配当データの取得

安定した配当: MORFの 1 株当たり配当が過去に安定していたかどうかを判断するにはデータが不十分です。

増加する配当: MORFの配当金が増加しているかどうかを判断するにはデータが不十分です。

配当利回り対市場

Morphic Holding 配当利回り対市場

MORF 配当利回りは市場と比べてどうか？
セグメント	配当利回り
会社 (MORF)	n/a
市場下位25% (US)	1.5%
市場トップ25% (US)	4.7%
業界平均 (Biotechs)	2.8%
3年後のアナリスト予想 (MORF)	n/a

注目すべき配当: MORFは最近配当金を報告していないため、配当金支払者の下位 25% に対して同社の配当利回りを評価することはできません。

高配当: MORFは最近配当金を報告していないため、配当金支払者の上位 25% に対して同社の配当利回りを評価することはできません。

株主への利益配当

収益カバレッジ: MORFの配当性向を計算して配当金の支払いが利益で賄われているかどうかを判断するにはデータが不十分です。

株主配当金

キャッシュフローカバレッジ: MORFが配当金を報告していないため、配当金の持続可能性を計算できません。

Morphic Holding 配当金

配当金 基準チェック /06

主要情報

最近の配当金アップデート

Recent updates

Here's Why We're Not Too Worried About Morphic Holding's (NASDAQ:MORF) Cash Burn Situation

Morphic Holding, Inc., Annual General Meeting, Jun 04, 2024

Morphic Therapeutic Appoints Simon Cooper as Chief Medical Officer

Consensus revenue estimates decrease by 88%, EPS upgraded

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

We're Hopeful That Morphic Holding (NASDAQ:MORF) Will Use Its Cash Wisely

Key Executive exercised options and sold US$174k worth of stock

Insufficient new directors

Price target decreased by 10% to US$55.13

Consensus EPS estimates upgraded to US$3.41 loss

Morphic Holding, Inc. Announces Chief Executive Officer Changes

Third quarter 2023 earnings released: US$0.73 loss per share (vs US$0.78 loss in 3Q 2022)

Companies Like Morphic Holding (NASDAQ:MORF) Are In A Position To Invest In Growth

Price target decreased by 13% to US$65.38

Morphic Holdings Inc. Announces Chief Executive Officer, Praveen Tipirneni Suffered an Emergent Medical Event and Taking Medical Leave of Absence

CFO & COO notifies of intention to sell stock

Second quarter 2023 earnings released: US$0.92 loss per share (vs US$0.70 profit in 2Q 2022)

CEO, MD & Director exercised options and sold US$190k worth of stock

We're Interested To See How Morphic Holding (NASDAQ:MORF) Uses Its Cash Hoard To Grow

General Counsel & Secretary notifies of intention to sell stock

Price target increased by 14% to US$73.88

Price target increased by 14% to US$73.88

First quarter 2023 earnings: EPS and revenues miss analyst expectations

CFO & COO exercised options to buy US$279k worth of stock.

CFO & COO notifies of intention to sell stock

Consensus revenue estimates decrease by 29%, EPS upgraded

Full year 2022 earnings: EPS and revenues exceed analyst expectations

President exercised options and sold US$358k worth of stock

What Does The Future Hold For Morphic Holding, Inc. (NASDAQ:MORF)? These Analysts Have Been Cutting Their Estimates

Morphic Holding, Inc. announced that it expects to receive $29.999954 million in funding

CEO, MD & Director exercised options and sold US$123k worth of stock

We're Hopeful That Morphic Holding (NASDAQ:MORF) Will Use Its Cash Wisely

Morphic Therapeutic AnnouncesInitiation of EMERALD-2 Phase 2b Clinical Trial of MORF-057 in Patients with Moderate-to-Severe Ulcerative Colitis

What Does The Future Hold For Morphic Holding, Inc. (NASDAQ:MORF)? These Analysts Have Been Cutting Their Estimates

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Morphic Therapeutic Presents New Positive MORF-057 Phase 1 Data at American College of Gastroenterology Annual Meeting 2022

Morphic Therapeutic Presents New Positive MORF-057 Phase 1 Data at UEG Week 2022

Consensus revenue estimates increase by 437%

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Morphic GAAP EPS of -$0.68 beats by $0.17, revenue of $60.2M

Price target decreased to US$66.43

Morphic Therapeutic Appoints Joanne Gibbons as Senior Vice President of Regulatory Affairs

Morphic Holding, Inc. Announces Management Appointments

Revenue Downgrade: Here's What Analysts Forecast For Morphic Holding, Inc. (NASDAQ:MORF)

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Morphic Holding, Inc., Annual General Meeting, Jun 08, 2022

Price target decreased to US$74.50

Morphic Therapeutic Announces Management Appointments

Chief Scientific Officer exercised options and sold US$367k worth of stock

Consensus revenue estimates fall by 38%

Analyst Forecasts Just Became More Bearish On Morphic Holding, Inc. (NASDAQ:MORF)

Price target decreased to US$75.80

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Morphic Holding, Inc. Announces Retirement of Dr. Nilesh Kumar from the Board and Resign as Member of the Board and the Audit and Nominating and Governance Committees

Here's Why We're Not Too Worried About Morphic Holding's (NASDAQ:MORF) Cash Burn Situation

Price target decreased to US$83.80

General Counsel & Secretary exercised options to buy US$827k worth of stock.

Price target decreased to US$95.00

Third quarter 2021 earnings released: US$0.69 loss per share (vs US$0.17 profit in 3Q 2020)

CFO & COO exercised options and sold US$246k worth of stock

We're Not Worried About Morphic Holding's (NASDAQ:MORF) Cash Burn

CFO & COO exercised options and sold US$1.3m worth of stock

Morphic: Pioneering Integrin Medicines

Chief Scientific Officer notifies of intention to sell stock

Founder recently bought US$4.2m worth of stock

Consensus EPS estimates fall to -US$2.73

Second quarter 2021 earnings released: US$0.77 loss per share (vs US$0.52 loss in 2Q 2020)

Morphic Holding (NASDAQ:MORF) Is In A Strong Position To Grow Its Business

Morphic Holding, Inc.(NasdaqGM:MORF) dropped from Russell 3000E Index

Insider notifies of intention to sell stock

Morphic Therapeutic to Present Positive Phase 1 Data for MORF-057 At ECCO'21 Virtual Congress

Founder recently bought US$11m worth of stock

Consensus forecasts updated

Independent Director has left the company

First quarter 2021 earnings released: US$0.64 loss per share (vs US$0.56 loss in 1Q 2020)

配当金基準チェック /06